Moderna

#Clinical trial #Covid-19 #Moderna

Positive data from Moderna study of Covid-19 vaccine in children 

Moderna has announced positive interim data from its Phase II/III study (KidCOVE) of mRNA-1273, the company’s vaccine candidate against Covid-19, in children six to 12 years of age.   This interim analysis showed a robust neutralising antibody response after two doses of mRNA-1273 at the 50µg dose level with a favourable… Read More

#News #Trending News

#AstraZeneca #Covid-19 #Immunology / Virology & Vaccines #Moderna #Pfizer

Health Canada approves Moderna, Pfizer and AstraZeneca vaccines 

Health Canada has approved Moderna’s New Drug Submission (NDS-CV) for Spikevax (elasomeran mRNA vaccine), it has granted full approval (Notice of Compliance or NOC) for Pfizer’s Comirnaty, and it has approved the AstraZeneca vaccine, which will be named Vaxzevria.  “Health Canada’s approval of our Covid-19 vaccine is an important milestone as it is our… Read More

#Covid-19 #News #Regulatory

#Clinical trial #Covid-19 #Immunology / Virology & Vaccines #Moderna #mRNA #Research

Moderna: new clinical data on its Covid-19 vaccine 

New analysis suggests that the Moderna Covid-19 vaccine is highly effective against circulating variants of concern, including in a vaccine effectiveness study conducted in partnership with Kaiser Permanente Southern California (KPSC) and in a separate recent publication by the US Centers for Disease Control and Prevention (CDC).   Additionally, the company shared… Read More

#Covid-19 #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines #Moderna #Regulatory

Moderna submits CMA for its Covid-19 vaccine booster  

Moderna has submitted a conditional marketing approval (CMA) with the European Medicines Agency (EMA) for the evaluation of a booster dose of the Moderna Covid-19 vaccine (mRNA-1273) at the 50 µg dose level.  “We are pleased to submit for a conditional marketing approval with the EMA for our booster candidate at the 50… Read More

#Covid-19 #News #Trending News

Covid-19
#Covid-19 #FDA #Immunology / Virology & Vaccines #Moderna #mRNA

Moderna submits initial data to FDA for Covid-19 vaccine booster 

Moderna has initiated its submission to the US Food and Drug Administration (FDA) for the evaluation of a booster dose of the Moderna Covid-19 vaccine (mRNA-1273) at the 50 µg dose level. The company expects to submit data to the European Medicines Agency (EMA) and other regulatory authorities around the world… Read More

#News

#Autoimmune disease #Clinical trials #Covid-19 #Immunology / Virology & Vaccines #Moderna #Pfizer

NIH studies Covid-19 vaccine dose for people with autoimmune disease 

The National Institutes of Health (NIH) has begun a clinical trial to assess the antibody response to an extra dose of an authorised or approved Covid-19 vaccine in people with autoimmune disease who did not respond to an original Covid-19 vaccine regimen.   The trial will also investigate whether pausing… Read More

#Covid-19 #News #Trending News

#Comirnaty #Covid-19 #FDA #Immunology / Virology & Vaccines #Moderna #Pfizer

This week in drug discovery (23-27 August) 

News round-up by DDW’s Megan Thomas for 23-27 August  The Covid-19 pandemic has undoubtedly put virology back on the drug discovery map and this week, DDW’s Megan Thomas has rounded up five stories which show updates and advancements in the fight against the virus.  … Read More

#News #Trending News

#Covid-19 #Immunology / Virology & Vaccines #Moderna

Japan suspends 1.6 million Moderna doses over contamination fears 

Japan has suspended the use of around 1.63 million doses of the Moderna vaccine due to contamination, which the health ministry confirmed resulted from “foreign materials” in an unused batch of roughly 560,000 vials, according to BBC reports.   According to the news site, Takeda Pharmaceutical, which sells and distributes… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #FDA #Immunology / Virology & Vaccines #Moderna #Regulatory

Moderna submits BLA to FDA for Covid-19 vaccine 

Moderna has completed the rolling submission process for its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for the full licensure of the its Covid-19 vaccine for active immunisation to prevent Covid-19 in individuals 18 years of age and older. As part of the completed BLA submission, Moderna has requested Priority… Read More

#Covid-19 #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines #Moderna #Oncology

Moderna’s Covid-19 vaccine maintains antibodies against variants 

New data has been published on the durability of the Moderna Covid-19 vaccine in generating neutralising antibodies against variants. The manuscript was published in Science.   “We are pleased with these new data showing that people vaccinated with two doses of the Moderna Covid-19 vaccine maintained antibodies through six months, including against variants… Read More

#Covid-19 #News

Covid-19
#Clinical trials #Covid-19 #Immunotherapy #Moderna #mRNA #Pfizer

Study on third Covid-19 vaccine dose in kidney transplant recipients 

A pilot study has begun to assess the antibody response to a third dose of an authorised Covid-19 mRNA vaccine in kidney transplant recipients who did not respond to two doses of the Moderna or Pfizer-BioNTech Covid-19 vaccine. The Phase II trial is sponsored and funded by the National Institute of Allergy and… Read More

#Covid-19 #News

#Covid-19 #Immunology / Virology & Vaccines #Moderna #mRNA

Third Covid-19 vaccine approved for immunocompromised

Moderna has announced that the U.S. Food and Drug Administration (FDA) has approved an update to the emergency use authorisation for the Moderna Covid-19 vaccine (mRNA-1273) to include a third dose for immunocompromised individuals. The third dose will available to people 18 years of age or older in the United… Read More

#Covid-19 #News

#Clinical trials #Covid-19 #Moderna #mRNA #Therapeutics

Moderna doses first patient with its IL-2 mRNA therapeutic candidate

Moderna has dosed the first patients in the Phase I study of mRNA-6231, the company’s mRNA-encoded IL-2, modified for the expansion of regulatory T cells. mRNA-6231 is Moderna’s first autoimmune candidate to enter the clinic and its first subcutaneously administered therapeutic program. “The initiation of the Phase I study of… Read More

#News #Trending News

#AI / data analytics / healthtech / informatics #Automation / robotics #Biopharmaceuticals #Covid-19 #CRISPR #Drug discovery #Immunology / Virology & Vaccines #Lab automation #Moderna #Molecular Biology #Pfizer #Sequencing

What has 2020 taught us about lab automation?

Listen to this article on the DDW Podcast: Dr Patrick Courtney (SiLA consortium), Burkhard Schaefer (SiLA consortium/ASTM AnIML) and Oliver Peter, Senior Director, Senior Group Leader Biology Technologies and Lead Discovery, Biology, Idorsia Pharmaceuticals, look at the importance of automation in the face of global disease. As we write this, vaccines… Read More

#Covid-19 #Exclusive Content #News

#Covid-19 #Immunology / Virology & Vaccines #Moderna #Vaccines

Moderna provides a clinical update on Delta variant immunity

Moderna has announced new results from in vitro neutralisation studies of sera from individuals vaccinated with the Moderna Covid-19 vaccine showing activity against variants of SARS-CoV-2. Vaccination with the Moderna Covid-19 vaccine produced neutralising titres against all variants tested, including additional versions of the Beta variant (B.1.351, first identified in… Read More

#News #Trending News

#Clinical trial #Clinical Trial Authorisation #Covid-19 #Immunology / Virology & Vaccines #Moderna #mRNA

Moderna initiates rolling submission of Biologics License Application (BLA)

Moderna has initiated the rolling submission process with the U.S. Food and Drug Administration for a Biologics License Application (BLA) for the licensure of its mRNA COVID-19 Vaccine to prevent COVID-19 in individuals 18 years of age and older. Stéphane Bancel, Chief Executive Officer of Moderna, said: “We look forward… Read More

#News #Trending News